Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41366-021-00804-7 http://scihub22266oqcxt.onion/10.1038/s41366-021-00804-7 33727631!7961323!33727631     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33727631&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Obes+(Lond) 2021 ; 45 (6): 1163-1169 Nephropedia Template TP {{tp|p=33727631|t=2021. Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics |pdf=|usr=}}{{33727631}} gab.com Text Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics JO: Int J Obes (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33727631 #FOAvip The COVID-19 pandemic has emerged as a public health crisis and has placed a significant burden on healthcare systems. Patients with underlying metabolic dysfunction, such as type 2 diabetes mellitus and obesity, are at a higher risk for COVID-19 complications, including multi-organ dysfunction, secondary to a deranged immune response, and cellular energy deprivation. These patients are at a baseline state of chronic inflammation associated with increased susceptibility to the severe immune manifestations of COVID-19, which are triggered by the cellular hypoxic environment and cytokine storm. The altered metabolic profile and energy generation of immune cells affect their activation, exacerbating the imbalanced immune response. Key immunometabolic interactions may inform the development of an efficacious treatment for COVID-19. Novel therapeutic approaches with repurposed drugs, such as PPAR agonists, or newly developed molecules such as the antagomirs, which block microRNA function, have shown promising results. Those treatments, alone or in combination, target both immune and metabolic pathways and are ideal for septic COVID-19 patients with an underlying metabolic condition. Twit Text FOAVip Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics ????Int J Obes (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33727631 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33727631 #FOAvip English Wikipedia <ref>{{Cite pmid|33727631}}</ref> Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics #MMPMID33727631 Batabyal R; Freishtat N; Hill E; Rehman M; Freishtat R; Koutroulis I Int J Obes (Lond) 2021[Jun]; 45 (6): 1163-1169 PMID33727631show ga The COVID-19 pandemic has emerged as a public health crisis and has placed a significant burden on healthcare systems. Patients with underlying metabolic dysfunction, such as type 2 diabetes mellitus and obesity, are at a higher risk for COVID-19 complications, including multi-organ dysfunction, secondary to a deranged immune response, and cellular energy deprivation. These patients are at a baseline state of chronic inflammation associated with increased susceptibility to the severe immune manifestations of COVID-19, which are triggered by the cellular hypoxic environment and cytokine storm. The altered metabolic profile and energy generation of immune cells affect their activation, exacerbating the imbalanced immune response. Key immunometabolic interactions may inform the development of an efficacious treatment for COVID-19. Novel therapeutic approaches with repurposed drugs, such as PPAR agonists, or newly developed molecules such as the antagomirs, which block microRNA function, have shown promising results. Those treatments, alone or in combination, target both immune and metabolic pathways and are ideal for septic COVID-19 patients with an underlying metabolic condition. |*COVID-19 Drug Treatment[MESH] |*COVID-19/immunology/metabolism/physiopathology[MESH] |*Diabetes Mellitus, Type 2/complications/drug therapy/physiopathology[MESH] |*Obesity/complications/physiopathology[MESH] |Antiviral Agents/therapeutic use[MESH] |Cytokine Release Syndrome[MESH] |Humans[MESH] |Hypoglycemic Agents/therapeutic use[MESH]Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology(epmc).pdf DeepDyve Pubget Overpricing